PCN127 Cost per Outcome Analysis of Nivolumab Versus Dabrafenib+Trametinib As Adjuvant Therapy for Patients with STAGE Iiib/C BRAF-Mutant Cutaneous Melanoma in Spain
Autor: | Ella X Du, J. Galan, T. Poretta, Andriy Moshyk, A. Amadi, K.A. Betts, M. Vembusubramanian, C. Polanco Sánchez |
---|---|
Rok vydání: | 2020 |
Předmět: | |
Zdroj: | Value in Health. 23:S445 |
ISSN: | 1098-3015 |
Databáze: | OpenAIRE |
Externí odkaz: |